Central Nervous System Glioma, Low-grade Glioma, Plexiform Neurofibroma
Conditions
Keywords
Glioma, Optic Pathway Glioma, Low grade glioma, MAPK/ERK, Plexiform Neurofibroma, Neurofibromatosis Type 1, Central Nervous System, CNS, Brain Tumor, LGG, NF1, KIAA1549-BRAF, Mitogen-activated Protein Kinase (MEK) inhibitor, Trametinib
Brief summary
This is a phase 2, open-label, interventional clinical trial that will study the response rate of pediatric glioma and plexiform neurofibroma (PN) to oral administration of trametinib. Patients meeting all inclusion criteria for a given study group will receive the study medication at a daily dose of 0.025 mg/kg up to a total of 18 cycles, in 28-day cycles. A total of 150 patients will be recruited as part of this clinical study. Patients aged between 1 month (corrected age) and 25 years old will be eligible, in order to include a maximum of patients affected by low-grade glioma (LGG) and PN. This study includes four groups: patients with neurofibromatosis type 1 (NF1) and LGG, NF1 patients with PN, patients with LGG with a B-Raf Serine/Threonine-protein Kinase/Proto-oncogene Encoding B-Raf (BRAF) fusion and patients with glioma of any grade with activation of the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinases (MAPK/ERK) pathway. All patients except patients with PN must have failed at least one line of treatment. The study will also explore the molecular mechanisms behind tumor development, progression and resistance to treatment. Furthermore, this study will also explore important aspects for patients with brain tumors by including assessment of quality of life and neuropsychological evaluation.
Interventions
DRUGTrametinib
Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
Sponsors
St. Justine's Hospital
Montreal Children's Hospital of the MUHC
CHU de Quebec-Universite Laval
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
There is no masking as part of this study. Only one study treatment will be given to all treatment groups at age and weight based dose.
Intervention model description
This trial will include 4 parallel groups. Each group will include a particular type of peripheral nerve or central nervous system tumor or mutation.
Eligibility
Sex/Gender
ALL
Age
1 Months to 25 Years
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent Prior to study participation, written informed consent from participants, or in the case of minors, written permission (informed consent) from parents, guardians, or legally acceptable representatives must be obtained according to local laws and regulations. 2. Assent Assent from minor participants should be obtained per local laws and regulations and should be documented in accordance with local requirements. 3. Study activities compliance. Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by contrast-enhanced MRI. 4. Age Patient must be aged ≥ 1 month (corrected age) to ≤ 25 years when starting trametinib. 5. Study group Participants must belong to one of the following groups to be eligible. Group 1: NF1 with progressing/refractory LGG Group 2: NF1 with PN Group 3: Progressing/refractory LGG with KIAA 1549-BRAF fursion Group 4: Progressing/refractory glioma with activation of the MPAK/ERK pathway who do not meet criteria for other study groups 6. Tumor Tissue Sample Tumor tissue will be required for all patients (minimally paraffin-embedded tissue block and additionally fresh frozen tissue \[if available\]). Patients with NF1 and LGG or PN can still be enrolled without tissue if no surgery or biopsy was conducted. 7 Previous MRI At least two previous MRIS fro Group 1, 3, 4 and one previous MRI for Group 2 must be available for central review. 8\. Prior therapy Participants must have failed at least one line of treatment including chemotherapy and/or radiation therapy except for plexiform neurofibroma (since there is no recognized standard treatment for his tumor). 9\. Prior therapy toxicity Patients must have recovered to grade ≤ 1 from acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy prior to enrollment except for alopecia and non-treatment related clinically insignificant laboratory abnormalities. prior to starting trametinib. Toxicities will be graded as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 10\. Prior therapy timeline Participants having previously received a chemotherapy agent(s) and/or radiation must conform to the timeline described below. There is no limitation on the number of previous treatments or cycles received. * An interval of at least 28 days after the last dose of a myelosuppressive chemotherapy, and at least 42 days after the last dose of Nitrosoureas is required prior to starting trametinib. * An interval of at least 28 days after the last dose of any biologic agents including monoclonal antibody treatment, immunotherapy, viral therapy and other investigational agent is required prior to starting trametinib. * An interval of at least 84 days after the end of the radiation therapy is required prior to starting trametinib. * An interval of at least 48 hours for short-acting colony stimulating factor agents and 10 days interval for long-acting colony stimulating factor agents are required prior to starting trametinib. 11\. Life expectancy Patients must have a life expectancy of greater than 6 months. 12\. Performance level Patients must have a performance status corresponding to a Lansky/Karnofsky score ≥50. 13\. Organ Function Requirements Participants must have normal organ and marrow function as defined below: * Total leukocytes ≥ 3,000/µL * Absolute neutrophil count (ANC) ≥ 1, 000/µL * Hemoglobin \> 80 g/l (transfusion independent within last 2 weeks prior to starting trametinib) * Platelet count ≥ 100,000/µL (transfusion independent within last 2 weeks prior to starting trametinib) * Total bilirubin ≤ 1.5 times the ULN within normal institutional limits for age * Alanine Aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN)\* * Creatinine serum within normal institutional limits for age OR creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. * Creatine phosphokinase ≤ 2x ULN * A cardiac function defined as Corrected QT (QTcB) interval \< 480 msec and LVEF ≥ lower limit of normal (LLN) by echocardiogram (ECHO). * Blood pressure must be smaller or equal to the 95th percentile for patient's age, height and gender. * For uniformity reasons, the ULN for ALT will be 45 U/L in this study 14\. Reproductive status Children of childbearing and child-fathering potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to starting trametinib and for the duration of study participation. Should a female become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Males and females treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib administration. Furthermore, females of childbearing potential (older than 10 years old for this study) must have a negative serum pregnancy test within 7 days prior to starting trametinib. A urine pregnancy test will be done according to evaluation calendar at at 30 days and at 6 months following the last does of study medications. 15\. Administration of oral medication Patients must be able to ingest and retain enterally (per os, nasogastric tube or gastrostomy) administered medication and be free of any clinically significant gastrointestinal abnormalities limiting the absorption of the medication. Tablets cannot be crushed. If the patient cannot swallow tablets, the liquid form should then be used. SPECIFIC INCLUSION CRITERIA Participants must belong to one of the following groups to be eligible. * Group 1: NF1 with Progressing/Refractory LGG (42 patients). * Group 2: NF1 with Progressing/Refractory PN (46 patients). * Group 3: Progressing/Refractory LGG with KIAA1549-BRAF fusion (42 patients). * Group 4: Progressing/Refractory CNS Glioma with activation of the MAPK/ERK pathway who do not meet criteria of other study groups (20 patients).
Exclusion criteria
1. Other investigational agents Patients who are receiving any other investigational agents. 2. Cardiac
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | From date of treatment start until the date of first documented progression, up to completion of treatment (504 treatment days). | Determination of the objective response rate of daily trametinib as a single agent for treatment of progressing/refractory low-grade tumors with MAPK/ERK pathway activation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression | From date of treatment start up to 3 years following completion of treatment (504 treatment days). | Time from treatment start, or censored at the date of last disease evaluation for those without progression reported. Applicable to group 1-2-3-4. |
| Progression Free Survival | From date of treatment start up to 3 years following completion of treatment (504 treatment days). | Time from treatment start to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at the date of last disease evaluation. Applicable to group 1-2-3-4. |
| Overall Survival | From date of treatment start up to 3 years following completion of treatment (504 treatment days). | Time from treatment start to death due to any cause, or censored at date last known alive. Applicable to group 1-2-3-4. |
| Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability). | From treatment start until 30-day follow-up visit. | Determination of the safety and tolerability of trametinib by assessment of toxicity associated with trametinib (Adverse Events (AEs), Serious Adverse Events (SAEs)). Applicable to group 1-2-3-4. |
| Determination of the Serum Level of Trametinib. | At Cycle 1 day 22 and at tumor progression OR on Day 1 of Cycle 16 (each cycle is 28 days long). | Determination of the serum level of trametinib by assessment of the through level. Applicable to group 1-2-3-4. |
| Evaluation of the Quality of Life During Treatment. | At screening, week 13, week 25, week 37, week 49, week 61 and at the end of treatment day 504. | Evaluation of the quality of life during treatment with the PedsQL cancer/brain tumor modules. Applicable to group 1-2-3-4. |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATORSébastien Perreault, MD
St. Justine's Hospital
Outcome results
None listed